InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2025-03-24 | George Whitesides(D-CA27) | house | Sale | $1,001 - $15,000 |
No financial data available for SDZNY.
Company may not file with SEC or CIK is unresolved.
Canada approves generic version of Novo's Ozempic
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength
Sandoz Group AG (SDZNY) Q1 2026 Sales/Trading Call Transcript
Sandoz Group AG (SDZNY) Q1 2026 Sales/ Trading Statement Call - Slideshow
Amneal 2026-2027 Upside From Biosimilars Scale
AMRX Growth Drivers: Generics, Biosimilars, and Crexont
Dermal Mycosis Market Research Report 2025-2026 & 2035, Competitive Analysis of Bayer, Kenvue, Karo Healthcare, Novartis, Glenmark Pharmaceuticals, Sun Pharma, Teva, and Sandoz
Novartis AG (NVS): One of the Best Low Risk High Growth Plays on the Market
Harmony Bio spikes after new Wakix patent litigation
Johnson & Johnson: Why I See Downside Ahead
Middle East and Africa Biosimilars Market Trends Report 2026-2035, Profiles of AbbVie, Amgen, Biocon, Celltrion, Dr. Reddy's, Pfizer, Roche, Samsung, Sandoz, Teva, Viatris
USNA vs. SDZNY: Which Stock Is the Better Value Option?